All In Biotech

Drug Trial Radar · NCT07714304

JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

A Phase II, Open-Label, Single-Arm Study of JS212 in Combination With JS111 as First-Line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jul 13, 2026

Primary completion

Nov 13, 2026

Study completion Jul 23, 2029

Sponsor

Lead sponsor
Huan ZhouAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm clinical study evaluating the safety, tolerability, and preliminary efficacy of JS212 in combination with JS111 as first-line treatment in participants with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received prior systemic therapy for advanced disease. The study consists of a safety lead-in stage followed by a clinical expansion stage. Approximately 20 participants are planned to be enrolled across the two stages. Participants will receive JS212 by intravenous infusion on Day 1 of each 21-day cycle and JS111 at 160 mg orally once daily until treatment discontinuation criteria are met. During the safety lead-in stage, up to 10 participants will be enrolled and monitored for significant toxicities during the first 21 days after initial administration. The Safety Monitoring Committee (SMC) will review available safety, tolerability, and efficacy data and determine the JS212 dose to be further evaluated, whether an additional higher or lower dose should be explored, and whether the study may proceed to the clinical expansion stage.

Conditions

  • NSCLC Harboring EGFR Mutations

Interventions

  • JS212 for InjectionDrug

    Administered by intravenous infusion on Day 1 of each 21-day cycle.

  • JS111 capsules (AP-L1898)Drug

    160 mg once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: up to 3 years
  2. Safety (AE)Time frame: up to 6 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.